2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type

Clinical Infectious Diseases

Volumn 63, Issue 12, 2016, Pages 1564-1573

  Zimmerman, Richard K ^a,g   Nowalk, Mary Patricia ^a   Chung, Jessie ^b   Jackson, Michael L ^c   Jackson, Lisa A ^c   Petrie, Joshua G ^d   Monto, Arnold S ^d   McLean, Huong Q ^e   Belongia, Edward A ^e   Gaglani, Manjusha ^f   Murthy, Kempapura ^f   Fry, Alicia M ^b   Flannery, Brendan ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^e MARSHFIELD CLINIC   (United States)

^f TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

influenza vaccine; vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ARTICLE; BODY MASS; CHILD; COINFECTION; DEMOGRAPHICS; DISEASE SEVERITY; HEALTH STATUS; HUMAN; IMMUNIZATION; INFLUENZA A; INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA VIRUS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT; PREDICTIVE VALUE; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UNITED STATES; VACCINATION; VIRUS DETECTION; ADOLESCENT; ADULT; AGED; FEMALE; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MIDDLE AGED; PRESCHOOL CHILD; VACCINE IMMUNOGENICITY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 85013656540     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw635     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Characteristics associated with seasonal influenza vaccination of preschool children—Oregon, 2006–2008. Morb Mortal Wkly Rep (MMWR) 2011; 60:981–4.
2. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014–15 influenza season. Morb Mortal Wkly Rep (MMWR) 2014; 63:691–7.
3. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis 2016; 213:1546–56.
4. Flannery B, Clippard J, Zimmerman RK, et al. Early estimates of seasonal influenza vaccine effectiveness—United States, January 2015. Morb Mortal Wkly Rep (MMWR) 2015; 64:10–5.
5. Skowronski DM, Chambers C, Sabaiduc S, et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–15 season. Clin Infect Dis 2016; 63:21–32.
6. Centers for Disease Control and Prevention. National and Regional Level Outpatient Illness and Viral Surveillance. Available at: http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. Accessed 17 February 2016.
7. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014–2015. J Infect Dis 2016; 214:1010–9.
8. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011–2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319–27.
9. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012–2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529–40.
10. International Classification of Diseases, Clinical Modification. Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 17 February 2016.
11. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 influenza season. Morb Mortal Wkly Rep (MMWR) 2015; 64:818–25.
12. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104–9.
13. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165–8.
14. Centers for Disease Control and Prevention. Interim adjusted estimates of seasonal influenza vaccine effectiveness—United States, February 2013. Morb Mortal Wkly Rep (MMWR) 2013; 62:119–23.
15. Flannery B, Thaker SN, Clippard J, et al. Interim estimates of 2013–14 seasonal influenza vaccine effectiveness—United States, February 2014. Morb Mortal Wkly Rep (MMWR) 2014; 63:137–42.
16. McElligott JT, Roberts JR, O’Brien ES, et al. Improving immunization rates at 18 months of age: implications for individual practices. Public Health Rep 2011; 126 (suppl 2):33–8.
17. Cost AA, Hiser MJ, Hu Z, et al. Brief report: mid-season influenza vaccine effectiveness estimates for the 2013–2014 influenza season. MSMR 2014; 21: 15–7.
18. Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. Vaccine 2016; 34:77–82.
19. Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog 2014; 10:e1003831.
20. O’Donnell CD, Vogel L, Matsuoka Y, Jin H, Subbarao K. The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines. J Virol 2014; 88:12374–84.
21. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016; 137:1–10.
22. Ambrose CS, Wu XH, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30:886–92.
23. Nowalk MP, Lin CJ, Toback SL, et al. Improving influenza vaccination rates in the workplace: a randomized trial. Am J Prev Med 2010; 38:237–46.
24. Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine 2003; 21:1486–91.